HUTCHMED says China NMPA approves ATLED for FGFR2-altered intrahepatic cholangiocarcinoma
HCM•Approval supported by China pivotal study
The approval was supported by a China pivotal Phase II/IIIb study showing a 42.5% objective response rate in pretreated advanced patients.
China approves ATLED for previously treated patients
China’s NMPA granted conditional clearance for ATLED (fanregratinib) to treat FGFR2 fusion/rearrangement intrahepatic cholangiocarcinoma in previously treated adults.
Related News
US nears deal to secure long-term access to Venezuela's oil reserves, sources say
XLE•
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option For Virologically Suppressed Adults With HIV, Including Those On Complex Regimens
GILD•
